Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT02907567




Registration number
NCT02907567
Ethics application status
Date submitted
5/09/2016
Date registered
20/09/2016
Date last updated
26/07/2018

Titles & IDs
Public title
Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease
Scientific title
A Randomized, Double-Blind, Placebo-Controlled, Phase I Study of the Safety & Pharmacokinetics of Two Doses of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease
Secondary ID [1] 0 0
COG0102
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Alzheimer's Disease 0 0
Condition category
Condition code
Neurological 0 0 0 0
Alzheimer's disease
Neurological 0 0 0 0
Dementias

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - CT1812
Treatment: Drugs - Placebo

Active Comparator: Active Treatment-Low - 6 subjects randomized to 280 mg (Low) CT1812

Active Comparator: Active Treatment-High - 6 subjects randomized to 560 mg (High) CT1812

Placebo Comparator: Placebo - 4 subjects randomized to matching placebo of CT1812


Treatment: Drugs: CT1812
Active study drug

Treatment: Drugs: Placebo
non-active study drug
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Incidence and review of Treatment Emergent Adverse Events
Timepoint [1] 0 0
Up to 30 days

Eligibility
Key inclusion criteria
1. Willing and able to provide written informed consent prior to initiation of any
study-related procedures. For subjects unable to provide written consent, consent will
be provided by the Person Responsible per local regulations.

2. Men and women, 50-80 years in age inclusively with a diagnosis of mild to moderate
Alzheimer's disease according to the 2011 NIA-AA. Women must be neither pregnant nor
nursing, and are either surgically sterile, postmenopausal or premenopausal using an
acceptable method of contraception.

3. Previous decline in cognition for more than six months.

4. Neuroimaging (MRI) obtained within the previous 6 months or during screening,
consistent with the clinical diagnosis of Alzheimer's disease.

5. MMSE 18-26 inclusive.

6. No active depression and a Geriatric Depression Score (GDS) of < 6.

7. Modified Hachinski Ischemia score = 4.

8. Formal education of eight or more years.

9. Living at home or in a community setting (assisted living) without continuous nursing
care. Each subject must have a reliable caregiver who sees them at least 3 times
weekly, can oversee the administration of study drug, and is willing and able to
participate in all clinic visits and some study procedures. Responsible caregiver must
provide written informed consent to participate.

10. Concurrent use of acetylcholinesterase inhibitors or memantine must be stable for 90
days prior to screening and not expected to change.
Minimum age
50 Years
Maximum age
80 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. History of or screening brain MRI scan indicative of significant abnormality,
including, but not limited to, prior hemorrhage or infarct > 1 cm3, >3 lacunar
infarcts, cerebral contusion, encephalomalacia, aneurysm, vascular malformation,
subdural hematoma, hydrocephalus, space-occupying lesion (e.g. abscess or brain tumor
such as meningioma).

2. Clinical or laboratory findings consistent with:

1. Other primary degenerative dementia,

2. Other neurodegenerative condition

3. Seizure disorder

4. Other infectious, metabolic or systemic diseases affecting the central nervous
system

3. A current DSM-V diagnosis of active major depression, schizophrenia or bipolar
disorder.

4. Clinically significant, advanced or unstable disease that may interfere with outcome
measures, and which may bias the assessment of the clinical or mental status of the
patient or put the patient at special risk

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 1/Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/09/2016
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/09/2017
Sample size
Target
Accrual to date
Final
19
Recruitment in Australia
Recruitment state(s)
QLD,VIC
Recruitment hospital [1] 0 0
Dr. Phillip Morris - Southport
Recruitment hospital [2] 0 0
Austin Health - Ivanhoe
Recruitment hospital [3] 0 0
Epworth Hospital - Melbourne
Recruitment hospital [4] 0 0
The Royal Melbourne Hospital Hospital - Parkville
Recruitment postcode(s) [1] 0 0
- Southport
Recruitment postcode(s) [2] 0 0
3079 - Ivanhoe
Recruitment postcode(s) [3] 0 0
3121 - Melbourne
Recruitment postcode(s) [4] 0 0
3050 - Parkville

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Cognition Therapeutics
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a multi-center, randomized, double-blind, placebo-controlled, parallel group study of
two doses of CT1812 in adults with mild to moderate Alzheimer's Disease to evaluate the
safety and tolerability of oral CT1812, administered for 28 days. This trial may include up
to 8 qualified investigator sites in Australia.
Trial website
https://clinicaltrials.gov/ct2/show/NCT02907567
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Michael Woodward, MD
Address 0 0
Austin Health
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT02907567